GENELINK RECEIVES NOTICE OF ALLOWANCE OF TRADEMARK: DERMAGENETICS™
November 5, 2003

MARGATE, NJ – (Business Wire) – November 5, 2003– GeneLink BioSciences, Inc. (OTCBB:GNLK) announced that the U.S. Patent & Trademark Office has issued a Notice of Allowance of GeneLink’s trademark, Dermagenetics™.

“Advances in skin care enabled by GeneLink’s Dermagenetics™ Profiles are imminent,” said John DePhillipo, GeneLink’s CEO. “A dramatic new series of anti-aging and anti-wrinkling skin creams based on GeneLink’s Dermagenetics™ Profiles, will soon be available for women and men, worldwide. A person will be able to visit a cosmetic counter and purchase customized skin cream based on GeneLink’s Dermagenetics™ Profiles.”

By analyzing an individual's DNA, which can be taken from the mouth with a cotton swab, it is possible to predict if he or she is prone to develop certain skin conditions, skin irritations, premature wrinkling and other risks related to oxidative damage, environmental stresses, and photo-aging.

GeneLink is the leader in the field of Dermagenetics™, the new science of utilizing gene technologies to measure a person’s predicted skin deficiencies. Dermagenetics™ facilitates the creation of skin care products and regimens scientifically designed to ameliorate a variety of skin health problems.

GeneLink now offers cosmetic companies the ability to create and market a powerful new class of ‘genetically guided’ skin-care products; these products are ultimately more effective because they are designed to target an individual’s specific needs.

GeneLink BioSciences, Inc. (www.genelink.info) since 1994, developed the World's First Family Centered DNA Bank and Hereditary Genetic Information Service.  With recent breakthroughs, GeneLink is a pioneer and leading provider of DNA tests created to facilitate “genetically guided” health, beauty and wellness products. The company both markets and licenses its proprietary tests to the $1.4 trillion cosmetics, nutritional supplement and healthcare industries.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.